Literature DB >> 17364849

Buprenorphine supply by community pharmacists in Victoria, Australia: perceptions, experiences and key issues identified.

Suzanne Nielsen1, Paul Dietze, Adrian Dunlop, Peter Muhleisen, Nicole Lee, David Taylor.   

Abstract

Buprenorphine is dispensed primarily in community pharmacies in Victoria, with buprenorphine prescribing expanding nationally. The aim of this paper was to examine issues that affect the delivery of buprenorphine in the community setting. A cross-sectional survey was conducted of 282 pharmacies participating in the methadone and buprenorphine programme across Victoria. Dispensing pharmacists completed the survey, designed to canvass issues around buprenorphine diversion and other issues related to the programme. Themes from the results indicated that there was concern from the majority of pharmacies with the issue of the supervision of buprenorphine and diversion of dispensed doses. The rate of suspected diversion was 1.5 times per 100 doses per month or 33 times per 100 clients per month. Seventy-four per cent of pharmacists indicated that this was a negative aspect of buprenorphine treatment. Frequency of suspected and confirmed diversion was associated with the number of pharmacy clients. Pharmacists' perceptions of issues related to buprenorphine appeared to affect opinions of buprenorphine clients and the buprenorphine programme more generally. Pharmacists believe that a significant level of diversion is occurring. This finding warrants serious attention, particularly in light of the increasing use of buprenorphine nationally and internationally.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17364849     DOI: 10.1080/09595230601146645

Source DB:  PubMed          Journal:  Drug Alcohol Rev        ISSN: 0959-5236


  9 in total

1.  Buprenorphine treatment for narcotic addiction: not without risks.

Authors:  Randy A Sansone; Lori A Sansone
Journal:  Innov Clin Neurosci       Date:  2015 Mar-Apr

2.  Community pharmacist engagement in opioid use disorder prevention and treatment behaviors: A descriptive analysis.

Authors:  Aaron Salwan; Nicholas E Hagemeier; Fred Tudiver; KariLynn Dowling-McClay; Kelly N Foster; Jessie Arnold; Arsham Alamian; Robert P Pack
Journal:  J Am Pharm Assoc (2003)       Date:  2020-07-12

3.  States' implementation of the Affordable Care Act and the supply of physicians waivered to prescribe buprenorphine for opioid dependence.

Authors:  Hannah K Knudsen; Michelle R Lofwall; Jennifer R Havens; Sharon L Walsh
Journal:  Drug Alcohol Depend       Date:  2015-10-09       Impact factor: 4.492

4.  Buprenorphine physician supply: Relationship with state-level prescription opioid mortality.

Authors:  Hannah K Knudsen; Jennifer R Havens; Michelle R Lofwall; Jamie L Studts; Sharon L Walsh
Journal:  Drug Alcohol Depend       Date:  2017-04-01       Impact factor: 4.492

5.  The Supply of Physicians Waivered to Prescribe Buprenorphine for Opioid Use Disorders in the United States: A State-Level Analysis.

Authors:  Hannah K Knudsen
Journal:  J Stud Alcohol Drugs       Date:  2015-07       Impact factor: 2.582

6.  Provision of opioid substitution therapy services in Australian pharmacies.

Authors:  B B Chaar; J R Hanrahan; C Day
Journal:  Australas Med J       Date:  2011-04-30

7.  Buprenorphine dispensing in an epicenter of the U.S. opioid epidemic: A case study of the rural risk environment in Appalachian Kentucky.

Authors:  Hannah Lf Cooper; David H Cloud; Patricia R Freeman; Monica Fadanelli; Travis Green; Connor Van Meter; Stephanie Beane; Umedjon Ibragimov; April M Young
Journal:  Int J Drug Policy       Date:  2020-03-26

8.  Australian Community Pharmacy Harm-Minimisation Services: Scope for Service Expansion to Improve Healthcare Access.

Authors:  Sara S McMillan; Hidy Chan; Laetitia H Hattingh
Journal:  Pharmacy (Basel)       Date:  2021-04-26

9.  Leveraging the role of community pharmacists in the prevention, surveillance, and treatment of opioid use disorders.

Authors:  Paxton Bach; Daniel Hartung
Journal:  Addict Sci Clin Pract       Date:  2019-09-02
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.